BGM Group Ltd.
BGMNasdaq
$0.28
↓ -3.5%Jul 17 close · end-of-day
Price
1Y↓ -97.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.0M
Enterprise Value
-$7.8M
P/E
—
P/S
0.1
P/B
0.0
EV/EBITDA
-11.6
PEG
—
FCF Yield
14.9%
Dividend Yield
—
Revenue (TTM)
$25.1M
Net Income (TTM)
-$1.4M
Free Cash Flow (TTM)
$304,105.00
Gross Margin
16.4%
Operating Margin
-2.3%
Net Margin
-5.8%
ROE
-3.4%
ROIC
-1.4%
Debt / Equity
—
Net Cash
$9.8M
Return 1Y
-97.1%
Company profile
Qilian International Holding Group Limited engages in the research, development, and production of active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human. In addition, it offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases.
- CEO
- Chen Xin
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 298
- Website
- qlsyy.net
Earnings
No reported earnings periods on file.
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $50.0M | $57.1M | $64.9M | $46.5M | $25.1M |
| Gross profit | $7.5M | $5.6M | $6.2M | $1.8M | $4.1M |
| Operating income | $4.8M | $2.4M | $2.1M | -$2.6M | -$563,771.00 |
| Net income | $5.1M | $3.2M | $1.1M | -$7.8M | -$1.4M |
| Diluted EPS | $0.17 | $0.09 | $0.15 | -$1.08 | -$0.20 |
| Operating cash flow | $5.1M | $345,034.00 | $12.7M | $312,209.00 | $544,238.00 |
| Free cash flow | $4.6M | -$1.1M | $10.6M | $132,450.00 | $304,105.00 |
| Gross margin | 15.1% | 9.9% | 9.6% | 3.8% | 16.4% |
| Operating margin | 9.6% | 4.2% | 3.2% | -5.6% | -2.2% |
| Net margin | 10.1% | 5.5% | 1.7% | -16.7% | -5.7% |
No quarterly data.
Company news
Feb 26, 2026
Jul 23, 2025
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.